A. Segura

发表

Prediction of Progression-Free Survival in Patients With Advanced, Well-Differentiated, Neuroendocrine Tumors Being Treated With a Somatostatin Analog: The GETNE-TRASGU Study

M. Marazuela, A. Lamarca, J. Valle, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

ESHAP is an active regimen for relapsing Hodgkin's disease.

J. Aparicio, A. Oltra, A. Segura, 1999, Annals of oncology : official journal of the European Society for Medical Oncology.

De Novo Internal Neoplasms after Liver Transplantation: Increased Risk and Aggressive Behavior in Recent Years?

J. Mir, M. Berenguer, A. Segura, 2004, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

EPCAM germ line deletions as causes of Lynch syndrome in Spanish patients.

R. Jover, C. Guillén-Ponce, A. Segura, 2010, The Journal of molecular diagnostics : JMD.

Prevalence of germline MUTYH mutations among Lynch-like syndrome patients.

I. Chirivella, C. Lázaro, G. Capellá, 2014, European journal of cancer.

Neoadjuvant cisplatin and etoposide, with or without tamoxifen, prior to radiotherapy in high-grade gliomas: a single-center experience

J. Aparicio, A. Segura, V. Calderero, 2005, Anti-cancer drugs.

High grade gliomas. Multidisciplinar treatment with radiotherapy and concurrent carmustine after surgery

J. Pérez-Fidalgo, R. Diaz-Beveridge, A. Segura, 2004 .

Vinorelbine, ifosfamide and cisplatin as first-line treatment in patients with inoperable non-small cell lung cancer.

S. Morales, C. Camps, A. Segura, 2001, Lung cancer.

Physician-perceived utility of the EORTC QLQ-GINET21 questionnaire in the treatment of patients with gastrointestinal neuroendocrine tumours: a multicentre, cross-sectional survey (QUALINETS)

Neus Canal, J. Capdevila, J. Gallego, 2021, Health and Quality of Life Outcomes.

Long-term results with oral fluoropyrimidines and oxaliplatin-based preoperative chemoradiotherapy in patients with resectable rectal cancer. A single-institution experience

J. Aparicio, S. Roldán, A. Segura, 2012, Clinical and Translational Oncology.

Clinical predictors of severe toxicity in patients treated with combination chemotherapy with irinotecan and/or oxaliplatin for metastatic colorectal cancer

J. Aparicio, A. Segura, J. Gomez-Codina, 2006, Medical oncology.

Adjuvant Chemoradiation in Gastric Cancer: Long-term Outcomes and Prognostic Factors from a Single Institution

J. Aparicio, C. García-Mora, M. Bennis, 2015, Tumori.

Management of controversial gastroenteropancreatic neuroendocrine tumour clinical situations with somatostatin analogues: results of a Delphi questionnaire panel from the NETPraxis program

R. García-Carbonero, J. Capdevila, E. Grande, 2016, BMC Cancer.

Evaluation of the efficacy and safety of lanreotide in combination with targeted therapies in patients with neuroendocrine tumours in clinical practice: a retrospective cross-sectional analysis

D. Castellano, J. Capdevila, E. Grande, 2015, BMC Cancer.

Antiproliferative effects of lanreotide autogel in patients with progressive, well-differentiated neuroendocrine tumours: a Spanish, multicentre, open-label, single arm phase II study

B. Massuti, D. Castellano, F. Rivera, 2013, BMC Cancer.

An internally validated new clinical and inflammation-based prognostic score for patients with advanced hepatocellular carcinoma treated with sorafenib

J. Aparicio, D. Lorente, R. Diaz-Beveridge, 2018, Clinical and Translational Oncology.

Evidence for classification of c.1852_1853AA>GC in MLH1 as a neutral variant for Lynch syndrome

Á. Carracedo, M. Andreu, A. Castells, 2011, BMC Medical Genetics.

An epidemiological evaluation of the prevalence of malnutrition in Spanish patients with locally advanced or metastatic cancer.

C. Jara, A. Segura, R. de las Peñas, 2005, Clinical nutrition.

Co‐occurrence of germline pathogenic variants for different hereditary cancer syndromes in patients with Lynch syndrome

A. Segura, V. Díez-Obrero, J. Soto, 2021, Cancer communications.

Heart Failure as First Sign of Development of Cardiac Metastases in a Patient with Diagnosis of Papillary Thyroid Carcinoma on Treatment with Tyrosine-Kinase Inhibitors: Differential Diagnoses and Clinical Management

R. Diaz-Beveridge, Ana Andrés, A. Segura, 2014, Case Reports in Oncology.

Neuroendocrine Tumor Heterogeneity Adds Uncertainty to the World Health Organization 2010 Classification: Real-World Data from the Spanish Tumor Registry (R-GETNE).

M. Marazuela, D. Castellano, R. García-Carbonero, 2018, The oncologist.

Cisplatin plus vinorelbine for patients with advanced head and neck squamous cell carcinoma.

J. Aparicio, A. Segura, A. Santaballa, 2000, The oncologist.

Initial clinical and treatment patterns of advanced differentiated thyroid cancer: ERUDIT study

V. Pubul, B. Castelo, J. Valdivia, 2022, European thyroid journal.

"Secondary cancers after Ewing sarcoma and Ewing sarcoma as second malignant neoplasm".

A. Verdeguer, J. Aparicio, V. Castel, 1998, Medical and pediatric oncology.

Peptide Receptor Radionuclide Therapy with [177Lu]Lu-DOTA-TATE in Patients with Advanced GEP NENS: Present and Future Directions

P. Bello, A. Segura, J. Merino-Torres, 2022, Cancers.

Cefepime monotherapy as an empirical initial treatment of patients with febrile neutropenia

J. Aparicio, A. Segura, V. Giner, 2002, Medical oncology.

Characterization of a novel POLD1 missense founder mutation in a Spanish population

A. Segura, V. Díez-Obrero, V. Barberá, 2017, The journal of gene medicine.

New insights into POLE and POLD1 germline mutations in familial colorectal cancer and polyposis.

C. Lázaro, G. Capellá, L. Valle, 2014, Human molecular genetics.

Prevalence and Clinicopathological Characteristics of Moderate and High-Penetrance Genes in Non-BRCA1/2 Breast Cancer High-Risk Spanish Families

I. Chirivella, A. Segura, I. Tena, 2021, Journal of Personalized Medicine.

BRCA1 and BRCA2 mutations in males with familial breast and ovarian cancer syndrome. Results of a Spanish multicenter study

J. Benítez, I. Chirivella, D. Salas, 2015, Familial Cancer.

Long-term results of neoadjuvant chemotherapy and combined chemoradiotherapy before surgery in the management of locally advanced oesophageal cancer: a single-centre experience

J. Aparicio, J. García, A. Segura, 2009, Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico.

Translational research in neuroendocrine tumors: pitfalls and opportunities

R. Salazar, D. Castellano, R. García-Carbonero, 2017, Oncogene.

Methylation of tumor suppressor genes is related with copy number aberrations in breast cancer.

Pascual Bolufer, Cristina Alenda, I. Chirivella, 2015, American journal of cancer research.

Implementation of massive sequencing in the genetic diagnosis of hereditary cancer syndromes: diagnostic performance in the Hereditary Cancer Programme of the Valencia Community (FamCan-NGS)

I. Chirivella, D. Salas, J. López-Guerrero, 2019, Hereditary cancer in clinical practice.

Guidelines for diagnosis, staging and treatment of metastatic colorectal cancer by Grupo Español Multidisciplinar en Cancer Digestivo (GEMCAD)

L. Cerezo, E. Espin, J. Aparicio, 2015 .

Analysis of clinical prognostic factors for survival and time to progression in patients with metastatic colorectal cancer treated with 5-fluorouracil-based chemotherapy.

J. Aparicio, J. Pérez-Fidalgo, A. Segura, 2003, Clinical colorectal cancer.

Long-term results after combined modality treatment for non-metastatic osteosarcoma

J. Aparicio, B. Munárriz, A. Oltra, 1999, Medical oncology.